[Diagnosis and treatment of juvenile idiopathic arthritis (JIA)]

Area of Science:

• Pediatric Rheumatology
• Immunology
• Chronic Disease Management

Background:

• Juvenile Idiopathic Arthritis (JIA) is a chronic inflammatory joint disease affecting children under 16.
• It presents with 7 clinical subtypes and impacts approximately 1 in 10,000 Japanese children.
• Established treatment strategies and disease activity assessment tools like JADAS exist.

Purpose of the Study:

• To review the current understanding of JIA management.
• To highlight the impact of advanced therapies on disease prognosis.
• To emphasize the importance of timely and appropriate treatment in JIA.

Main Methods:

• Review of established JIA treatment protocols.
• Analysis of the efficacy of biologic agents in refractory JIA cases.
• Evaluation of the role of JADAS in assessing treatment response.

Main Results:

• Biologic agents have shown remarkable improvement in disease course and joint prognosis for refractory JIA.
• Treatment efficacy can be reliably assessed using tools like JADAS.
• Current challenges in JIA prognosis are linked more to treatment delays than disease severity.

Conclusions:

• Early and appropriate treatment is crucial for improving the prognosis of Juvenile Idiopathic Arthritis.
• Biologic therapies offer significant benefits for patients unresponsive to conventional treatments.
• Rheumatologists must prioritize prompt and accurate treatment to mitigate poor outcomes in JIA.